Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a biotechnology company focused on transforming adaptive immune system genetics into clinical products, announced that its cutting-edge clonoSEQ® test for measurable residual disease (MRD) will feature prominently at upcoming major medical conferences. The American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from May 31 to June 4, and the European Hematology Association (EHA) Hybrid Congress in Madrid from June 13 to 16, will include multiple oral and poster presentations showcasing the utility of clonoSEQ.
Susan Bobulsky, Chief Commercial Officer at Adaptive Biotechnologies, highlighted the importance of these presentations, emphasizing the significant role of MRD testing in the rapidly evolving blood cancer treatment landscape. She remarked that clonoSEQ remains the gold standard for MRD assessment, providing critical insights for clinicians and drug developers.
MRD status, a vital indicator in blood cancer prognosis, helps personalize treatment plans by monitoring patient responses, detecting early relapse signs, and optimizing care strategies. Clinically, clonoSEQ technology is extensively used in drug development to gauge treatment efficacy and define response depth and kinetics. The technology is increasingly serving as a primary endpoint in clinical trials.
Key study highlights to be presented include:
- A Children's Oncology Group study on pediatric acute lymphoblastic leukemia (ALL) demonstrated a strong correlation between MRD assessments from bone marrow and peripheral blood using clonoSEQ, suggesting a less invasive monitoring method.
- Real-world evidence from multiple myeloma (MM) cases underscored the clinical relevance of sustained MRD negativity, linking deeper responses with better overall survival (OS) and progression-free survival (PFS).
- Data from the University of Chicago’s MRD2STOP study showed that MRD testing with clonoSEQ could identify patients suitable for safely discontinuing maintenance therapy while maintaining MRD negativity.
- The PERSEUS study by Clinica Universidad de Navarra revealed that MRD negativity at deeper levels correlated with improved PFS, particularly in patients receiving daratumumab (D) in combination with bortezomib/lenalidomide/dexamethasone (VRd).
- Several trials highlighted clonoSEQ's role in evaluating novel CAR-T therapies, showing that MRD negativity predicts PFS in challenging patient groups.
- Data on chronic lymphocytic leukemia (CLL) from clinical trials demonstrated that clonoSEQ supports individualized MRD-guided treatment adjustments.
The presentations at ASCO and EHA will cover various aspects of blood cancers, including B-cell acute lymphoblastic leukemia, multiple myeloma, follicular lymphoma, and chronic lymphocytic leukemia. Specific presentation titles and timings were listed, indicating a comprehensive display of clonoSEQ's clinical benefits across different cancer types.
clonoSEQ, the only FDA-cleared in vitro diagnostic test for MRD detection in MM or B-ALL patients from bone marrow and CLL from blood or bone marrow, leverages Adaptive Biotechnologies’ proprietary platform. This platform identifies and quantifies specific malignant DNA sequences, providing accurate and sensitive MRD measurements that are critical for predicting patient outcomes, monitoring treatment responses, and early relapse detection.
Adaptive Biotechnologies is a commercial-stage biotechnology company translating adaptive immune system genetics into diagnostic and therapeutic products. Their immune medicine platform aids in developing clinical diagnostics and partnering with biopharmaceutical companies to advance drug development. Their focus includes diseases like cancer, autoimmune disorders, and infectious diseases.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!